Avatar

Ambulatory Blood Pressure Monitoring

By William White
August 12, 2016
10 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
06:38
Allan Jaffe

What Does Elevated Troponin Mean in COVID-19?

10:41
Houston Methodist DeBakey Heart and Vascular Center

2020 High Blood Pressure Guidelines: When Is BP Too High?

Feat. A. Marie Navar
21:52
Terumo Aortic

How to Minimize Air Embolisms During Thoracic Endovascular Aortic Repair

Feat. M. Kreibich
28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty Acids…

Feat. R. Mason
01:49
Philips

A Message to Healthcare providers around PAD and PVD

Feat. F. Fakorede
42:27
Physicians Committee for Responsible Medicine

Hypertension Management & Nutrition: What Are the Key Nutrients for Bl…

Feat. V. Rahman
18:10
University of Colorado Department of Medicine

Understanding Pathophysiology of Preeclampsia: How Are Advancements Provid…

Feat. M. Hladunewich
18:25
ARCH Advanced Revascularization Symposium

Hypertension 2016: Guidelines and Updates

06:32
Mayo Clinic Proceedings

Premature Atrial Contraction Frequency and Cognitive Function

Feat. L. Yee Chen
28:22
Richard Auchus

Primary Aldosteronism and Implications for Primary Hypertension

15:14
Cardiometabolic Health Congress (CMHC)

PAD in Patients with (a Risk of) Cardiometabolic Disease: What Is the Corr…

Feat. D. Bhatt
21:10
National Lipid Association

Plant-based Diets for Improving Lipids

Feat. K. Williams
09:38
George Bakris

Hyperkalemia in Chronic Kidney Disease

15:45
National Lipid Association

Management of Atherogenic Dyslipidemia and Atherosclerosis: What Are PPARs…

Feat. S. Subramanian
27:08
Fifth Annual Clinical Advances in the Diagnosis and Management of Pulmonary Hypertension

Diagnosis and Management of Pulmonary Arterial Hypertension in Chronic Lun…

Feat. K. Fan
18:43
Bonita Falkner

Recent Advances in Pediatric Hypertension

17:56
National Lipid Association

Update on Evinacumab: ANGPTL3 and Lipid Management

Feat. P. Duell
24:35
Keck School of Medicine of USC

Role of Lipoprotein(a) in Coronary Disease: What CV Risks Can you Expect? …

Feat. S. Nissen
17:04
Cardiometabolic Health Congress (CMHC)

Part 2 - What Have We Learned from the CANTOS Trial and Looking Forward?

Cleveland Clinic Heart, Vascular and Thoracic Institute

Effect of Left Ventricular Conduction Delay on Cardiovascular Mortality

Feat. D. Cantillon